Page 3 - Sanket Koul

Union Budget 2026-27: Over ₹1 trillion earmarked for the nation's health

Biopharma Shakti initiative to tackle burden of non-communicable diseases, turn India into global, innovation-led hub

Education Budget jumps to ₹1.39 trillion, school learning gets record push

School education and learning receive their highest-ever allocation as Budget 2026-27 raises overall education spending by over 8 per cent, with higher outlays for KVs, IITs and new initiatives

FM announces ₹10,000 crore scheme to promote biopharma manufacturing

Finance Minister Nirmala Sitharaman announced Mission Biopharma Shakti in the Budget, a five-year ₹10,000 crore programme to build domestic capabilities in biologics, biosimilars and clinical research

Centre proposes amendment to allow drug imports via Navi Mumbai airport

Health Ministry proposes listing Navi Mumbai International Airport as a notified port under drug rules, enabling air import of medicines through the facility

Dr Lal PathLabs Q3 net profit falls 6.4% on new labour code impact

Diagnostics major reports a one-time charge linked to new labour codes even as revenue rose over 10% on higher sample volumes and network expansion

IBM signs 10-year lease for 230,000 sq ft office space in Gurugram

US technology major leases space at Tata Realty's Intellion Park as demand for offices in tier-I cities stays strong and absorption continues to outpace new supply

Economic Survey 2026: Obesity fast becoming a public health challenge

Economic Survey flags rising lifestyle diseases and obesity in India, urging stricter regulation and warning labels on ultra-processed foods to curb health risks

Govt moves to curb cheap penicillin-based drug imports for 1 year

Centre imposes one-year minimum import price on key penicillin inputs to check Chinese dumping and protect domestic bulk drug manufacturing

Eco Survey flags need for skill courses to curb dropouts in classes 9-12

The Economic Survey 2025 calls for skill-embedded education in classes 8-12 to tackle high dropout rates driven by income pressure and limited access to secondary schools

Eco Survey urges education reforms, global push to curb student exodus

India must reform higher education and promote international student programmes to curb brain drain and boost its global education presence

Centre puts stricter controls on pregabalin sales over abuse concerns

India has moved pregabalin to Schedule H1, tightening prescription and record-keeping norms after states flagged widespread misuse of the nerve pain drug for intoxication

Centre scraps prior approval system for BA/BE studies of low-risk drugs

The health ministry has amended clinical trial rules to replace prior approvals for low-risk BA/BE studies with simple online intimations, a move aimed at cutting delays, easing compliance

India-EU FTA: Indian pharma to get stronger dose of EU market access

EU's zero-tariff offer on most chemical and medical exports is set to boost India's pharma, medtech and biosimilars access to European markets

India-EU FTA boosts Europe's appeal for Indian students amid visa flux

India-EU FTA's focus on mobility could expand choices for Indian students, making Europe a more deliberate study destination even as the US remains key amid uncertainty over visa policies

Antimicrobial sales growth set to temper in 2026 over govt's AMR push

Stricter rules to curb antimicrobial resistance may limit antibiotic sales growth in 2026, as India tightens OTC use and pushes prescription-led, responsible consumption

Centre mandates blue chip on all antimicrobial brand labels to counter AMR

In a gazette notification dated January 23, the Union health ministry proposed adding a new clause under Rule 95 of the Drugs Rules, 1945

Syngene downgrades its revenue guidance by 5% on Librela inventory impact

Syngene trims FY26 revenue guidance by up to 5% as inventory correction for veterinary drug Librela hits profits, even as core research and CDMO business grows

DLF gears for senior housing entry, eyes sales in Mumbai, Panchkula in FY27

Developer says Q3 sales dropped due to Dahlias pause, no new launches

DLF Q3 FY26 results: PAT up 13.6%, revenue rises 42% on high net income

Realty major states gross zero debt on high net cash position

Zydus Lifesciences launches cancer drug Nivolumab's biosimilar in India

Move comes just months before nivolumab patent expiry in India on May 2, 2026